ArticleDrug delivery2020
Adjudin-loaded redox-sensitive paclitaxel-prodrug micelles for overcoming multidrug resistance with efficient targeted Colon cancer therapy.
Article in Drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Review
- Antibody conjugation of paclitaxel enables aqueous compatibility and enhances tumor-targeted efficacyFrontiers in pharmacology · 2026Article
- Natural product-based nanotechnological formulations for colorectal cancer treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Polymeric Micelles in Colorectal Cancer Therapy: A Comprehensive Review of Nano-drug Delivery Strategies, Copolymer Types, Physicochemical Characteristics, and Therapeutic Applications.Current medicinal chemistry · 2025Review
- Enzyme-catalyzed synthesis of selenium-doped manganese phosphate for synergistic therapy of drug-resistant colorectal cancer.Journal of nanobiotechnology · 2023Article
- Synergistic antitumor efficacy of PD-1-conjugated PTX- and ZSQ-loaded nanoliposomes against multidrug-resistant liver cancers.Drug delivery and translational research · 2022Article
- Micelles as potential drug delivery systems for colorectal cancer treatment.World journal of gastroenterology · 2022Review
- Recent Advances in Stimuli-Sensitive Amphiphilic Polymer-Paclitaxel Prodrugs.Frontiers in bioengineering and biotechnology · 2022Review
- A novel redox-responsive ursolic acid polymeric prodrug delivery system for osteosarcoma therapy.Drug delivery · 2021Article
- Cascaded amplification of intracellular oxidative stress and reversion of multidrug resistance by nitric oxide prodrug based-supramolecular hydrogel for synergistic cancer chemotherapy.Bioactive materials · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance (MDR) is the primary cause for the failure of chemotherapy in the treatment of colon cancer. Recent research has indicated that the combination of a chemotherapeutic agent and a mitochondrial inhibitor might represent a promising strategy to help overcome MDR. However, for this approach to be clinically effective, it is important that the two drugs can be actively and simultaneously delivered into tumor cells at an optimal ratio and completely released drug within cells. To address these challenges, we designed and prepared a folate receptor-targeted and redox-responsive drug delivery system (FA-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.